Vemurafenib

Key Product Details

Product Description

Vemurafenib is a potent inhibitor of BRAF^V600E, C-Raf and wild type B-Raf (IC₅₀ values are 13-31 nM, 6.7-48 nM and 100-160 nM, respectively. Vemurafenib also inhibits SRMS, ACK1 KHS1, FGR (IC₅₀ values are 18 nM, 19 nM, 51 nM and 63 nM, respectively). Vemurafenib shows antitumor activity and induces autophagy in BRAF-mutant thyroid cancer cells.

Product Specifications for Vemurafenib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Vemurafenib

The following data is based on the product molecular weight 489.92.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.04 mL	10.21 mL	20.41 mL
5 mM	0.41 mL	2.04 mL	4.08 mL
10 mM	0.20 mL	1.02 mL	2.04 mL
50 mM	0.04 mL	0.20 mL	0.41 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ibrahim Chapter twenty-six - case history: vemurafenib, a potent, selective, and first-in-class inhibitor of mutant BRAF for the treatment of metastatic melanoma. Annu.Rep.Med.Chem.
• Davis and Schlessinger The genesis of zelboraf: targeting mutant B-Raf in melanoma. J.Cell.Biol. 2012 PMID: 23027900
• Wang Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J.Clin.Endocrinol.Metab. 2017 PMID: 27754804

Product Documents for Vemurafenib